| CAS NO: | 145-13-1 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| 50g | 电议 |
| 100g | 电议 |
| Molecular Weight (MW) | 316.48 |
|---|---|
| Formula | C21H32O2 |
| CAS No. | 145-13-1 (Pregnenolone); |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 22 mg/mL (69.5 mM) |
| Water: <1 mg/mL | |
| Ethanol: 22 mg/mL (69.5 mM) | |
| Other info | Chemical Name: 1-((3S,8S,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethan-1-one InChi Key: ORNBQBCIOKFOEO-QGVNFLHTSA-N InChi Code: InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1 SMILES Code: O[C@H](C1)CC[C@@]2(C)C1=CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@H]4C(C)=O |
| Synonyms | 3β-Hydroxy-5-pregnen-20-one; NSC 1616; NSC 18158; NSC1616; NSC18158; NSC-1616; NSC-18158; Prenolon; Regnosone; Skinostelon; Enelone; Natolone; Pregnetan; Pregneton; Pregnolon. |
| In Vitro | In vitro activity: Pregnenolone induces a large, dose-related increase of both the rate and extent of MAP2-induced tubulin assembly, whereas progesterone, inactive per se, counteracted the stimulatory effect of Pregnenolone. Pregnenolone-increased assembly of microtubules produces a completely normal structure. Pregnenolone preserves microtubule abundance and promotes cell movement during epiboly. Pregnenolone results in dramatic reduction in GR nuclear localization in mouse hippocampal cell line (HT-22). Pregnenolone has neuroprotective effects against both glutamate and amyloid beta protein neuropathology. |
|---|---|
| In Vivo | Pregnenolone sustains its proliferative activity in vivo and stimulates the growth of LNCaP-tumor xenografts in intact male SCID mice as well as in castrated animals. Pregnenolone is shown to activate transcription through the LNCaP androgen receptor (AR), but not the wild-type AR. Pregnenolone results in a significant decrease in the accumulation of astrocytes in the proximity of the wound and in a decreased bromodeoxyuridine incorporation in reactive astrocytes of rats. Pregnenolone administration results in elevations in downstream neurosteroids such as allopregnanolone, a molecule with neuroprotective effects that also increases neurogenesis, decreases apoptosis and inflammation, modulates the hypothalamic-pituitary-adrenal axis, and markedly increases GABA(A) receptor responses. Pregnenolone administration elevates pregnenolone sulfate, a neurosteroid that positively modulates NMDA receptors. |
| Animal model | Mice and rats |
| Formulation & Dosage | Adult male Wistar rats (weighing 320-340g), Sprague Dawley male rats (weighing 330-350g), C57BL/6N mice (2-3 months) and CD1 mice (weighing 25-30 g at the beginning of the experiments) are used. Pregnenolone is injected subcutaneously (sc). The injection volumes are 1 mL/kg of body weight for rats and 10 mL/kg for mice |
| References | Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3579-84; Nature. 2006 Jan 26;439(7075):480-3; Int J Dev Neurosci. 1999 Apr;17(2):145-51. |
m.cnreagent.com